Clinical trial NCT04699032: Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.
Official title: A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Renal Function.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Chronic Kidney Disease
Keywords: Renal Function
Renal Impairment
Kidney Function
Lead sponsor: VectivBio AG
Sponsor class: INDUSTRY
First posted: 2021-01-07
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Study of pharmacokinetics and safety of apraglutide in participants with normal and impaired kidney function.

Detailed description: A two stage design, open label, multi-center, non-randomized trial to evaluate the PK and safety of a single subcutaneous dose of 5 mg apraglutide in subjects with varying degrees of renal function. The renal function was calculated by the estimated glomerular filtration rate (eGFR) according to the Chronic Kidney Disease Epidemiology (CKD-EPI) Creatinine Equation.

Part 1: 8 subjects with severe renal impairment (Cohort 1) and 8 subjects with normal renal function (Cohort 2).

Part 2: 8 subjects with moderate (Cohort 3) and 8 subjects with mild (Cohort 4). Enrollment into Part 2 was conditional on the results of Part 1.

Eligibility criteria: Inclusion Criteria:

All Participants

* Age between 18 and 75 years inclusive
* Subjects who are willing and able to comply with the study procedures
* Subjects able to understand and willing to sign the informed consent
* Body mass index (BMI) of ≥17.5 to ≤40 kg/m2; and a total body weight of \>50 kg (110 lb).
* Women of childbearing potential (WOCBP) on highly effective method of contraception during the trial and for 1 month after the end of trial (EOT) visit. Sterilized or infertile or postmenopausal females.
* Male subjects with a female partner of childbearing potential: highly effective methods of contraception and no sperm donation during the trial and for 1 month after (EOT) visit.

Healthy participants

* No clinically relevant abnormalities (medical history, vital signs, ECG, safety labs)
* eGFR measured by CKD-EPI ≥90 mL/min/1.73 m2) at two screening visits
* Demographically comparable to the group of subjects with impaired renal function:

Participants with impaired renal function

* Severe renal impairment: eGFR \<30 mL/min/1.73 m2, but not requiring hemodialysis
* Moderate renal impairment: eGFR ≥30 mL/min/1.73 m2 and \<60 mL/min/1.73 m2
* Mild renal impairment: eGFR ≥60 and \<90 mL/min/1.73 m2

Exclusion Criteria:

All Subjects

* Renal transplant recipients
* History of systemic infection
* Any active malignancies or history of malignancies within the past 2 years
* Acute or chronic medical or psychiatric condition
* Treatment with an IMP within 30 days or 5 half-lives (whichever is longer) preceding the dose of IMP
* Male subjects partners of WOCBP who are unable to comply with the contraceptive measures
* History of clinically significant intestinal adhesions and/or chronic abdominal pain
* History of known colon polyps or family history of familial adenomatous polyposis
* Positive blood screen for hepatitis C antibody, hepatitis B surface antigen or human immunodeficiency virus (HIV)-1 and -2 antibodies
* Serum albumin concentration \<25 g/L (2.5 g/dL)
* Hemoglobin concentration \<90 g/L (9.0 g/dL)
* Aspartate amino transaminase (AST) or alanine amino transaminase (ALT) values \>2 × upper limit of normal (ULN)
* Proteinuria of \>3 g total bilirubin \>1.5 × ULN
* Positive urine test for alcohol or illicit drugs at either Screening or admission.
* Clinically significant abnormalities on 12-lead ECG
* Use of prescription or non-prescription drugs and dietary supplements within 7 days or five half-lives (whichever is longer) prior to Day 1. Stable concomitant medications may be given to subjects with renal impairment, if they are considered necessary for the welfare of the subjects.
* History of regular alcohol consumption exceeding seven drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces \[150 mL\] of wine, or 12 ounces \[360 mL\] of beer, or 1.5 ounces \[45 mL\] of hard liquor) within 3 months of Screening
* Female subjects of childbearing potential who are unwilling or unable to use highly effective methods of contraception for the duration of the trial and for at least 1 month after the administration of the IMP; pregnant female subjects; female subjects planning to become pregnant during the duration of the trial and until 1 month after the administration of the IMP; breastfeeding female subjects
* Blood donation of approximately 500 mL or more within 60 days prior to the dose of IMP. Plasma donations of approximately 500 mL or more within 28 days prior to the dose of IMP

Additional Exclusion Criteria for Healthy Subjects with Normal Renal Function

* Evidence or history of clinically significant abnormalities
* Evidence or history of clinically significant dermatological condition

Additional Exclusion Criteria for Subjects with Impaired Renal Function

* Subjects requiring hemodialysis and/or peritoneal dialysis
* Subjects with other clinically significant disease
* Subjects with any significant hepatic, cardiac, or pulmonary disease or subjects who are clinically nephrotic. Hypertension, diabetes mellitus, hyperparathyroidism, ischemic heart disease are not cause for exclusion as long as the subject is medically stable and any drugs that are administered for these conditions are not expected to interfere with the PK of apraglutide.
* Screening BP ≥180 mmHg (systolic) or ≥110 mmHg (diastolic)

Primary outcomes:
measure: Maximum Plasma Concentration (Cmax) of Apraglutide
timeFrame: 5 minutes pre-dose up to 240 hours after dosing on Day 1
measure: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of Apraglutide
timeFrame: 5 minutes pre-dose up to 240 hours after dosing on Day 1
Secondary outcomes:
measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
timeFrame: Day 1 up to Day 14
measure: Number of TEAEs
timeFrame: Day 1 up to Day 14
Other outcomes:
Locations:
city: Orlando
country: United States
facility: Orlando Clinical Research Center
state: Florida
city: Saint Paul
country: United States
facility: Prism Clinical Research, Inc.
state: Minnesota
Study officials:
affiliation: VectivBio AG
name: Tomasz Masior
role: STUDY_DIRECTOR
References: